{"id":12399,"date":"2003-12-01T05:44:07","date_gmt":"2003-12-01T05:44:07","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=12399"},"modified":"2014-05-27T10:33:30","modified_gmt":"2014-05-27T10:33:30","slug":"fosamprenavir-lexiva-approved-in-us","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/12399","title":{"rendered":"Fosamprenavir (Lexiva) approved in US"},"content":{"rendered":"<p><strong>On 20 October the US Food and Drug Administration approved the protease inhibitor fosamprenavir (Lexiva, GW908). Fosamprenavir is a pro-drug of amprenavir (Agenerase). This new formulation requires fewer pills than amprenavir (now usually four pills a day including the ritonavir, vs. 16 pills a day for Agenerase), and no food restrictions.<\/strong><\/p>\n<p>European approval is expected to follow in about six months and until then fosamprenavir remains available on an expanded access programme.<\/p>\n<p>Information for doctors and patients is at:<br \/>\n<a href=\"http:\/\/www.lexiva.com\"> http:\/\/www.lexiva.com<\/a><\/p>\n<p>Other links:<\/p>\n<p>Brief review by the FDA of the pivotal clinical trials:<br \/>\n<a href=\"http:\/\/www.thebody.com\/fda\/lexiva.html?m18\"> http:\/\/www.thebody.com\/fda\/lexiva.html?m18<\/a><\/p>\n<p>GSK review:<br \/>\n<a href=\"http:\/\/www.gsk.com\/press_archive\/press2003\/press_10212003a.htm\"> http:\/\/www.gsk.com\/press_archive\/press2003\/press_10212003a.htm<\/a><\/p>\n<p>An extensive review by the activist organisation TAG (Treatment Action Group), supporting approval &#8211; but only when Lexiva is \u201cboosted\u201d with a low dose of ritonavir to increase blood levels of Lexiva:<br \/>\n<a href=\"http:\/\/www.aidsinfonyc.org\/tag\/tx\/fosamprenavir.html\"> http:\/\/www.aidsinfonyc.org\/tag\/tx\/fosamprenavir.html<\/a><\/p>\n<p>Combinations, adverse events, dosing, interactions, resistance:<br \/>\n<a href=\"http:\/\/www.hivandhepatitis.com\/hiv_and_aids\/lexiva_1.html\"> http:\/\/www.hivandhepatitis.com\/hiv_and_aids\/lexiva_1.html<\/a><\/p>\n<p><strong>Source: AIDS Treatment News<br \/>\n<\/strong><a href=\"http:\/\/www.aidsnews.org\">http:\/\/www.aidsnews.org<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>On 20 October the US Food and Drug Administration approved the protease inhibitor fosamprenavir (Lexiva, GW908). Fosamprenavir is a pro-drug of amprenavir (Agenerase). This new formulation requires fewer pills than amprenavir (now usually four pills a day including the ritonavir, &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-12399","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/12399","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=12399"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/12399\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=12399"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=12399"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=12399"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}